杭州，2026年8月18日——国际类器官研究协会2026临床转化高峰论坛今日在杭州滨江世融艾美酒店举办。 Just when it seemed that Vaa Vaathiyaar was finally ready to arrive in theatres, the film has run into fresh legal trouble that may delay its release yet again. The Karthi led entertainer, directed by Nalan Kumarasamy, was recently confirmed for a December 12 opening. However, the Madras High Court has now issued an interim order restraining the film’s release, a development that has left fans and trade watchers anxiously waiting for clarity.High Court Restraint Casts Doubt on the Film’s ArrivalThe legal dispute originates from a long-standing case involving producer KE Gnanavel Raja of Studio Green. According to the petition filed by the Official Assignee of the High Court, the producer has outstanding dues linked to a film project that dates back to 2011. As per records submitted in court, Gnanavel Raja and businessman Sunderdas had entered into an agreement to co-produce a film, with both parties expected to invest forty crore rupees each. Sunderdas is said to have contributed 12 crore and 85 lakh rupees before stepping away from the project.In 2014, the High Court declared Sunderdas insolvent and appointed the Official Assignee to evaluate his financial liabilities. Upon review, the Assignee has reportedly found that Gnanavel Raja still owes ten crore and 35 lakh rupees to the insolvent estate. This prompted the Assignee to file a petition in 2016, seeking a directive for repayment along with interest at eighteen percent per year from 2013. The matter has remained pending and has now resurfaced at a critical moment for Vaa Vaathiyaar.
The Court has currently placed a stay on the release of the film until December 5, with the next hearing scheduled for December 8. Whether the makers will secure permission to proceed with the planned release remains to be seen.A Promising Collaboration Caught in UncertaintyVaa Vaathiyaar marks the first union between Karthi and filmmaker Nalan Kumarasamy, a pairing that has generated considerable excitement. The film is positioned as an action comedy with a quirky premise. While the makers have kept most story details confidential, early buzz suggests that Karthi plays a police officer who admires the late actor and politician MG Ramachandran. In a fantastical twist, his character is believed to be possessed by the spirit of the former Chief Minister while investigating a case.Krithi Shetty plays the female lead, while the supporting cast features respected names including Rajkiran, Sathyaraj, Anandaraj, Karunakaran, GM Sundar, Shilpa Manjunath and Ramesh Thilak. The film also boasts a strong technical team. Cinematographer George C Williams handles the visuals, Vetre Krishnan edits the film, Santhosh Narayanan composes the music, and DRK Kiran serves as art director.The project has built steady hype not only for its star power but also for Nalan’s return to the director’s chair, a move that fans have been anticipating for years. For Karthi, who is coming off the success of films like Sardar and Ponniyin Selvan, Vaa Vaathiyaar promises a lighter and more playful outing.For now, the focus shifts to the court proceedings. The hope within the industry is that the legal issues will be resolved swiftly so that the film can arrive without further setbacks.
Also Read: Karthi’s Vaa Vaathiyaar Locks Release Date。本次论坛由国际类器官研究协会（ISoOR）主办，艾名医学（ISoOR中国秘书处）承办，以“从生物模型到可信证据——类器官的标准化与临床实践”为主题，汇聚国内外科研、临床、产业与投资界代表，围绕类器官从前沿生物模型迈向规模化临床应用的关键路径展开交流，共同推动行业标准化与高质量发展。论坛同时宣布启动国际类器官研究与产业转化中心（International Center for Organoid Research and Enterprise，ICORE）。ICORE由ISoOR发起，定位为集前沿研究、技术验证、临床转化、产业孵化与国际合作于一体的国际化创新平台。
论坛开幕ISoOR主席Peter E. Lobie院士致欢迎辞并宣布论坛开幕。他表示，类器官技术的临床转化已进入关键阶段，其结果能否稳定复现、证据能否获得临床信任、质量体系能否支撑规范应用，仍是类器官走向临床必须解决的核心问题。本届论坛聚焦类器官临床应用、新药研发、标准化、自动化与国际互认等议题，希望各界专家分享实践经验、探讨发展路径、凝聚广泛共识，共同推动类器官行业进步。
主题演讲精彩回顾在临床转化方向，中国医药质量管理协会医学检验质量管理专业委员会主任委员、原西部战区总医院实验室医学中心主任吴丽娟教授结合最新政策指出，论坛召开前夕，国家医疗保障局已将肿瘤类器官培养与药物敏感性检测相关项目纳入《检验类医疗服务价格项目立项指南（试行）》，为临床应用提供了政策保障，专家共识、质量标准则是类器官技术在临床应用落地的基础。
二 | 此前，她还牵头制定了《患者来源的肿瘤组织器官培养及药物敏感性检测的专家共识》，为患者来源肿瘤类器官培养及药敏检测的规范开展提供专业指引。四川大学华西医院刘嘉烨教授则从临床证据层面，介绍了其团队开展的“基于甲状腺癌类器官导向晚期患者治疗的Ⅱ期临床试验”成果，其中甲状腺未分化癌患者总体客观缓解率达到50%；基于相关临床证据，《甲状腺癌类器官药物敏感性检测临床应用专家共识（2025版）》正式发布。
三 | 随着临床研究证据的持续积累，专家共识与质量标准建设，医疗服务价格项目规范，临床应用进程有望进一步加快。
在新药研发方向，成都中医药大学申重阳教授分享类器官在新药研发及致病机制研究中的最新进展：其团队在顶级期刊《Cancer Letters》发表的研究中，58例肺癌患者样本成功构建类器官进行药敏检测，预测临床响应的总准确率达 87.1%，"AI+类器官"模式在高通量药物筛选、药物临床前评价体系、临床肿瘤耐药机制突破三大领域展现出广阔应用前景。中国科学院广州生物医药与健康研究院郭雅琼研究员介绍了团队研发的标准化、自动化智能实验平台。
四 | 该平台可将类器官药敏检测周期由人工培养通常所需的21天缩短至5—7天。前沿模型与自动化、标准化智能平台的结合，在提升类器官药物筛选与评价效率的同时，也为肿瘤患者在治疗“黄金窗口期”内获得药敏检测结果和用药参考提供了技术支撑。
在再生医学方向，中国科学院杭州医学研究所李亮教授展示了类器官模型在眼科疾病精准治疗中的应用探索。他开展的“眼脑通路重建”研究，探索了通过视网膜类器官移植治疗视神经损伤的可能性，并有望解决视网膜移植治疗中供体严重不足的困境。
在国际标准方向，ISoOR秘书长Maldonado Martin博士介绍了ISoOR与ISoOR-AB在构建全球协调的类器官生物样本库标准化与认可框架方面的合作进展，以及相关国际标准从制定走向实施的具体行动。国际标准化组织（ISO）类器官工作组委员、艾名医学COO周轶博士分享了全球类器官产业创新发展图景，并介绍了类器官国际标准化的进程，进一步凝聚了行业对标准化、可信证据与协同转化的共识。
五 | 
圆桌讨论以“从生物模型到可信证据：类器官临床转化的未来路径”为主题，由周轶博士主持，华西医院甲状腺科李志辉主任，浙江省人民医院样本库刘小珍主任，同写意新药英才俱乐部创始理事长、贝壳学社荣誉校长朱迅教授和富磐资本创始合伙人陈磊泉先生共同参与。与会嘉宾围绕类器官技术如何完成从科研到临床、从技术到应用的跨越展开对话，并就医院、样本库、产业与资本如何加强协同、构建产业闭环进行深入探讨，为类器官从科研证据走向临床应用、产业落地提供了多元视角。
